News

June 23, 2021

Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

Vancouver, British Columbia – June 23, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific […]
Read More >

June 9, 2021

Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

Vancouver, British Columbia – June 9, 2021 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >

May 12, 2021

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

Vancouver, British Columbia – May 12, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific […]
Read More >